Integrated Diagnostics (IDHC) Q1 2026 TU earnings summary

Executive summary

• Achieved 31% year-over-year revenue growth in Q1 2026 to EGP 2.1 billion, driven by a 22% increase in test volumes and a 7% rise in average revenue per test.

• Net profit surged 78% year-over-year to EGP 437 million, with adjusted net profit (excluding FX gains) up 36% to EGP 292 million.

• Expanded branch network by 153 locations year-over-year, reaching 794 branches, with significant growth in Egypt, Jordan, Nigeria, and Saudi Arabia.

• Egypt contributed 85% of group revenue, with broad-based growth across all core markets.

• Seasonal effects from Ramadan and Eid moderated revenue growth and weighed on margins.

Financial highlights

• Gross profit increased 28% year-over-year to EGP 807 million; gross margin at 38.9%.

• EBITDA rose 23% to EGP 611 million; EBITDA margin at 29.5%.

• Net cash balance at EGP 1,855 million as of March 31, 2026, up from EGP 1,662 million a year earlier.

• Cost of goods sold rose 33% to EGP 1,266 million, with raw materials as a share of revenue improving to 18.7%.

• SG&A expenses increased 32% to EGP 350 million, stable at 16.9% of revenue.

Outlook and guidance

• Focus remains on disciplined expansion, operational efficiency, and deepening specialised diagnostics capabilities.

• Plans to launch three additional branches in Saudi Arabia, targeting further growth in the region.

• Management closely monitoring regional developments and macroeconomic conditions.